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Introduction
Surveillance of patients at high risk of cancer recurrence aims to detect relapsed disease soon after it develops. In theory, this should maximise treatment options, including surgical resection [1] . Additionally, treatments that improve clinical outcomes may be more effective in patients with low volume disease [2, 3] .
Stage 3 melanoma is associated with a high risk of recurrence that is dependent on sub-stage [4, 5] . Despite this, no approaches for imaging surveillance are uniformly accepted and National Comprehensive Cancer Network (NCCN) guidelines have been developed largely by consensus rather than data [6] . As for other cancers, imaging surveillance in melanoma has not yet been linked to improved outcomes [7, 8] or economic benefits [7] .
Several studies found that surveillance imaging does not discover melanoma recurrence in most patients [9] [10] [11] [12] [13] . In the largest report, recurrence was detected first by imaging in only 53% [5] . While most series evaluated chest X-ray (CXR) or CT, recent studies indicate that PET is more sensitive for detecting metastatic disease [14] . However, there are limited data regarding PET surveillance [15] [16] [17] [18] .
Approaches to melanoma surveillance are typically similar regardless of the relapse risk of individual patients. The NCCN recommends imaging with CXR, CT or PET every 3-12 months [6] , even though different disease sub-stages have different patterns of relapse. We thus prospectively applied sub-stage-specific imaging surveillance to patients via a multi-disciplinary melanoma clinic at the Peter MacCallum Cancer Centre. Whole body PET and MRI brain scanning were used, given their improved sensitivity compared with CT [14] . Imaging time points were tailored according to pre-test probabilities that recurrent disease would be present at specific time points. Here we sought to define the sensitivity, specificity and predictive values of such surveillance in patients with resected stage 3 melanoma.
Methods

Patient selection
The study was ethics-approved (PMCC 13/179). Patients were identified from the institutional PET database if they had proven melanoma and had undergone PET between 2009 and 2016. Patients were excluded because of relapse before planned surveillance, inadequate documentation, substantial deviation from recommended surveillance, mucosal or uveal melanoma, or stage 2 or 4 disease.
FDG-PET acquisition
After fasting, patients were injected with 3.6 MBq/kg (610%) of FDG and rested for 60 min. Patients were scanned from vertex to proximal thighs unless the primary lesion was in a lower limb, in which case the scan was extended. A CT was acquired for attenuation correction and anatomical localization using 120 kV, 40À130 SMART mA, pitch 1.35, slice thickness 3.75 mm and rotation time 0.5 s. The PET was acquired at 3 min per bed step.
Data collection
Clinical data (patient demographics, pathology, imaging outcomes, time to relapse, treatment) were retrieved from medical records. If PET reports were equivocal, changes were considered suspicious of relapse if subsequent clinical management changed (e.g. treatment of relapse, biopsy, increased scan frequency).
Statistical analysis
Clinical data were summarized using descriptive statistics. True positive (TP) imaging relapses were confirmed histologically or radiologically, or treated with antimelanoma therapy. False positive (FP) findings were suspicious of melanoma relapse but found to be histologically benign or non-progresive on serial scans. Incidental findings unrelated to melanoma were negative results. True negative (TN) findings indicated melanoma non-recurrence at subsequent time points. Imaging findings were false negative (FN) if disease recurrence was confirmed subsequently at defined time points. Stage 3A and 3B/C patients who did not complete 18 and 36 months of surveillance, respectively, were censored for analysis unless there was intervening TP, FP or FN.
Results
Imaging surveillance protocol design
Published data [5] were analysed to estimate sub-stage-specific pre-test probabilities of melanoma recurrence (supplementary Table S1 , available at Annals of Oncology online). Based on this, the probability of recurrence in stage 3A patients decreased steadily after the first post-operative year, during which $15% of patients recurred. The higher first year rates of recurrence in stage 3B/C patients (32% and 42%, respectively) were maintained for at least two years following surgery.
Accordingly, 6 monthly PET scans were recommended for the first 2 years in stage 3B/C patients, with an additional scan at 36 months. An MRI brain was recommended at 6 and 12 months for stage 3C only, based on risks of brain-only relapse [5] . For stage 3A, PET scans at 6 and 18 months were recommended, based on lower risks of recurrence compared with 3B/3C patients (supplementary Table S2 , available at Annals of Oncology online).
Study population
A total of 356 melanoma patients were identified on the PET database. After exclusions (supplementary Figure S1 , available at Annals of Oncology online), PET scans from 170 patients were analysed (stage 3A: 20%, 3B: 55%, 3C: 25%). Baseline characteristics of these (supplementary Table S3 , available at Annals of Oncology online) were typical. The median follow-up was 47 months. During the evaluation period, 65 patients developed recurrent disease. Rates of recurrence in each stage-specific subgroup were 3A: 32%, 3B: 38% and 3C: 44%.
True and FP relapses
In total, 77 patients (45% of the whole cohort) were suspected to have melanoma relapse, of which 57 (34%) had asymptomatic PET changes (supplementary Figure S2 , available at Annals of Oncology online). Of these suspected relapses, 45 (26%) were deemed true positives (TP) either because initial imaging was unequivocal and immediate treatment was required (N ¼ 2), or after the performance of extra imaging (N ¼ 17), biopsy (N ¼ 8), or both (N ¼ 18). For the 12 (7%) patients with FP PET findings in whom relapse was not confirmed, 10 had biopsies that were negative and 2 normalized their imaging. One patient subsequently relapsed after having a FP scan. Twenty (12%) patients had clinical signs or symptoms suggestive of relapse that was confirmed by imaging, biopsy or both in all but one case. These were considered failures of PET surveillance. No relapses were identified by clinician examination without being first reported by patients.
Per scan predictive values of PET surveillance
A total of 502 PET scans were carried out. Thirty-two of 34 stage 3A, 80 of 93 stage 3B, and 37 of 43 stage 3C patients completed a minimum of 18 months (3A) and 36 months (3B and 3C) of surveillance. In 87% (129/147) of censored patients, at least 50% of scans were carried out within 4 months of the protocol-designated time. The positive predictive values (PPV) of an individual PET scan for detecting disease ranged from 56% [95% confidence interval (CI): 28%-80%] in stage 3A to 83% (CI: 62%-94%) in stage 3C (Table 1) patients. Across all disease stages, negative predictive values (NPV) of each scan were high (93%-97%) for predicting non-recurrence within 30-days (Table 1) . A negative PET was highly predictive (3A: 89%; 3C: 96%) of non-recurrence before the next planned scan (Table 1) .
We also evaluated PET scans at each time point for their ability to predict non-recurrence for the remainder of the study follow-up period. In this context, a FN scan was defined as emergence of recurrent disease before censoring the study at median 47-months follow-up. A negative PET 6 months after surgery was only modestly predictive (57%-64%) of subsequent non-recurrence, but at 18-months was highly predictive (80%-84%) ( Table 1) .
Per patient predictive values of PET surveillance
We next examined as a whole the application of sub-stagespecific PET surveillance protocols in each patient. In this analysis, the completion of each protocol, comprising multiple scans for each sub-stage, was considered as a single 'test', such that a suspicious finding on any scan was included as a 'positive result' and accepted as a TP if confirmed. Accordingly, a FN result was defined as a recurrence that was not detected asymptomatically on a previous scan. For patients with >1 outcome (e.g. FP at one time point and TP at a later time point; N ¼ 3), we denoted the most clinically meaningful outcome as a 'single outcome' based on the following ranking order: FN > FP > TP > TN.
By this evaluation, sub-stage-specific PET surveillance had overall per patient sensitivities and specificities of 70% (95% CI: 57%-81%) and 87% (95% CI: 78%-93%), respectively ( Table 2) . PPVs of the whole PET scanning protocol for detecting disease relapse were relatively low for stage 3 A patients (55%) but high for 3B/C patients (83%). NPVs ranged from 74% (3A) to 82% (3B) ( Table 2) .
In a separate contingency analysis that included PET-detected new asymptomatic non-melanoma neoplasia's as TPs, overall sensitivity and PPV improved to 72% (60%-82%) and 82% (71%-89%). This was most noticeable in patients with stage 3A disease, in which sensitivity improved to 54% and PPV to 64%.
Method of detection and site of first relapse
Of the 19 true relapses that were symptomatic, 11 were locoregional and eight distantly metastatic. First relapses were more likely to be loco-regional in stage 3A (50%) than in stage 3B/3C patients (33%). In stage 3A/3B, most common sites of distant relapse were lung, lymph nodes and bone. In stage 3C, metastatic disease involved various organs.
Of the 59 MRI brain scans carried out on 43 patients, brain recurrences were detected in 5 patients (3%). Three of these were either symptomatic at the time of scanning or occurred with widespread disease and one was evident as an area of suspicious avidity on PET. Only one was a truly asymptomatic brain-only recurrence.
Management of relapse
Curative-intent resection was undertaken as initial therapy in 33 (52%) relapsed patients, with 10 (16%) disease-free at median 24 months (Figure 1 ; supplementary Figure S2 and Table S4 , available at Annals of Oncology online). Seventy three percent of 
Incidental findings
Incidental findings not suspicious of melanoma were detected 43 times in 39 (23%) patients. This included 11 diagnoses of nonmelanoma neoplasia in 10 (6% of all patients) patients [breast angiosarcoma, colorectal cancer/high grade dysplasia (N ¼ 2), meningioma (N ¼ 3), lung cancer, tonsillar squamous cell cancer, diffuse large B cell lymphoma, and one patient with both prostate and colon cancer]. Eight of these were treated with curative intent (supplementary Figure S3 , available at Annals of Oncology online). Other incidental findings included sarcoidosis (n ¼ 2), abdominal aortic aneurysms (n ¼ 2), intracerebral aneurysms (n ¼ 2), non-specific inflammation (n ¼ 5), ovarian cysts (n ¼ 2) and others (e.g. parathyroid nodule, Hashimoto's thyroiditis, fat necrosis, hepatic abscess, cyst, cholelithiasis and eosophagitis).
Discussion
We found that post-operative surveillance imaging of stage 3 melanoma patients with PET has high sensitivity, specificity and NPV for detecting asymptomatic recurrence of disease. The latter may provide reassurance for patients with a negative scan. Indeed, a normal PET scan at 18-months conferred a 20% chance of recurrence in the 47-month median follow-up period. Most ($70%) recurrences in our study were asymptomatic before detection by PET. This contrasts with studies of other modalities that found most recurrences first detected by patients rather than imaging. The higher rate of asymptomatic detection in our cohort may reflect improved sensitivity of PET for detecting recurrence.
Caveats of our study are worth noting. Although our patients underwent prospective application of imaging surveillance, our data were collected retrospectively and relied on clinical and imaging reports, the latter occasionally requiring interpretation as to whether recurrence was suspected. Our identification of patients from a PET database rather than all patients with stage 3 disease enriched for better prognosis patients by excluding early recurrences that developed before surveillance. This explains why our stage 3A and 3C rates of recurrence were more and less than expected, respectively, relative to stage 3B. However, imaging surveillance will never benefit patients with very early relapse. We also caution extrapolation of our data to populations with different pre-test probabilities, as PPV and NPV are products of 'event' prevalence. Further, our cohort was surveyed in the era before effective adjuvant therapies [19] whose potential impact on PET surveillance is not known, and when completion lymphadenectomies were more common than currently [20] , which may alter the dynamics of locoregional recurrence patterns. In addition, there was no comparator arm to compare PET surveillance with other imaging modalities such as CT, although PET is typically preferred for detection of metastatic melanoma [14] . Finally, costs of surveillance [21] were not recorded in our study. Of course, these would be offset if early treatment of metastatic melanoma improves outcomes and if high NPVs reduce need for frequent monitoring.
A risk of imaging surveillance is the possibility of FP findings causing 'scanxiety' or leading to invasive investigations. Previously, PET in stage 3A melanoma was associated with an 8% FP rate [16] . In our study, 7% of all patients had FP PET findings and 6% underwent biopsy to determine this. However, one of the prerequisites of imaging surveillance is a high sensitivity to identify early recurrence at the potential cost of high specificity and FPs. Patients undergoing surveillance should be informed of the implications of suspicious imaging findings, including anxiety, FP findings and potential for biopsies. This is particularly relevant for stage 3A patients, given the low specificity in this Figure 1 . Sub-stage-specific recurrences rates in defined post-operative time periods categorized by total recurrences, whether curative intent treatment was delivered, and whether these were asymptomatic relapses. x-Axis denotes time period after surgery (months) and y-axis denotes % of all patients in each sub-stage-specific cohort who relapsed.
subgroup. However, these concerns should be balanced against the reassurance of a negative scan. The FP rate in our study was offset by the discovery of curable incidental malignancies (6% of all patients) and the high proportion (52%) of relapsed patients offered curative-intent surgery. Overall, 11% of all relapsed patients had their recurrent melanoma detected asymptomatically by PET in a manner that enabled resections to render them disease-free at censor date. Furthermore, the high rate of discovery of asymptomatic but unresectable disease by surveillance PET meant that systemic therapy could be offered to patients with lower disease burden [2, 3, 22] .
Data support the use of PET for staging [23, 24] or evaluating therapy response in melanoma [25] . However, there are limited reports for detection of recurrence after resection [15] [16] [17] [18] . In addressing this, our study suggests reasonable, evidence-based approaches to PET surveillance in stage 3 melanoma. A key feature of our approach is its sub-stage specificity, which was designed using Bayesian estimates of pre-test probability [5] that recurrent disease would be present at defined time points. This is an essential component of rational surveillance that minimizes unnecessary scans and maximizes early detection of recurrence.
For stage 3A patients, although the risk of FP results is high, PET at 6 and 18 months should identify most asymptomatic recurrence, and an additional scan at 24-30 months might be justified to identify late recurrences, which developed steadily in our cohort (Figure 1 ). For stage 3B, 6-monthly surveillance with PET appears warranted to 36 months, when the risk of recurrence remains substantial, and we suggest an additional scan at $48 months, when the chance of recurrence is $10% (supplementary Table S1 , available at Annals of Oncology online) [5] , but none thereafter. For stage 3C patients, in which recurrence rates are high in the first year [5] (Figure 1 ; supplementary Table S1 , available at Annals of Oncology online), a PET at $3 months could be added to our protocol to optimize early detection of relapsed disease. However, the probability of recurrence diminishes substantially in stage 3C beyond 2-years [5] , after which more scanning is arguably not necessary. More data are required to make recommendations about brain surveillance, as although we detected fewer than expected brain metastases, the devastating effects of these are worth avoiding if possible by early detection and treatment. Decisions to scan beyond any recommended time point need to consider individual factors such as patient anxiety and the increasing likelihood of FP results as the pre-test probability of true recurrence diminishes.
Despite these suggestions, it is notable that surveillance in melanoma with PET or other modalities has not been linked to improved survival. In Markov modelling, PET every 6 months detected surgically treatable recurrence in 33% of stage 3 patients, and it was extrapolated that 26 PET scans would be needed to detect a resectable recurrence in stage 3C disease [8] . However, this was based on several assumptions, including that only 20% of imaging-detected recurrences are resectable, which is lower than reported [26] and the $50% of relapsed patients who underwent surgical resection in our cohort.
Conclusion
The use of imaging surveillance in melanoma needs to be reconsidered in the current era. Early detection of asymptomatic disease could increase the proportion of patients who are offered curative-intent surgery and/or systemic therapies whose benefits are maximized. For such surveillance, disease sub-stage-specific schedules of PET surveillance offer high rates of detection of asymptomatic recurrence, opportunities for early therapeutic intervention, and high NPVs that may provide reassurance to patients. Randomized prospective evaluation is needed to quantitate the survival, quality of life and economic impacts of PET surveillance compared with other imaging modalities, or no surveillance.
